Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients

Shinichi Saito, Nagahide Takahashi, Ryoko Ishihara, Masashi Ikeda, Tatsuyo Suzuki, Tsuyoshi Kitajima, Yoshio Yamanouchi, Nakao Iwata, Mitsuhiko Yamada, Keizo Yoshida, Toshiya Inada, Norio Ozaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Vesicle-associated membrane protein 2 (VAMP2) is a key component of the synaptic vesicle docking/fusion machinery and its mRNA reportedly increases in the frontal cortex of rats following chronic antidepressant and electroconvulsive treatment. VAMP2 is therefore thought to be involved in the mechanism of action of antidepressants and may alter their efficacy. The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine. Methods: A total of 106 patients with major depressive disorder were given fluvoxamine (50-200 mg/day) for 8 weeks and assessed for severity of depression using the Semi-Structured Interview Guide of the Hamilton Depressive Scale (SIGH-D; 17 items) at 0 and 8 weeks. We defined a clinical response as more than a 50% reduction in baseline SIGH-D within 8 weeks, and defined clinical remission as a SIGH-D score of less than 7 at 8 weeks. Genotyping was performed by PCR-RFLP. Results: Analysis of haplotype tagging single nucleotide polymorphisms as well as haplotype analysis did not reveal any significant associations. Conclusion: Our results suggest that the VAMP2 gene is unlikely to play a major role in the efficacy of fluvoxamine.

Original languageEnglish
Pages (from-to)226-230
Number of pages5
JournalNeuropsychobiology
Volume54
Issue number4
DOIs
Publication statusPublished - 01-04-2007

Fingerprint

Vesicle-Associated Membrane Protein 2
Fluvoxamine
Antidepressive Agents
Haplotypes
Genes
Synaptic Vesicles
Major Depressive Disorder
Frontal Lobe
Restriction Fragment Length Polymorphisms
Single Nucleotide Polymorphism
Interviews
Depression
Polymerase Chain Reaction
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Neuropsychology and Physiological Psychology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Saito, Shinichi ; Takahashi, Nagahide ; Ishihara, Ryoko ; Ikeda, Masashi ; Suzuki, Tatsuyo ; Kitajima, Tsuyoshi ; Yamanouchi, Yoshio ; Iwata, Nakao ; Yamada, Mitsuhiko ; Yoshida, Keizo ; Inada, Toshiya ; Ozaki, Norio. / Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. In: Neuropsychobiology. 2007 ; Vol. 54, No. 4. pp. 226-230.
@article{822b4ae71ad04fcab95030353a205f83,
title = "Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients",
abstract = "Background: Vesicle-associated membrane protein 2 (VAMP2) is a key component of the synaptic vesicle docking/fusion machinery and its mRNA reportedly increases in the frontal cortex of rats following chronic antidepressant and electroconvulsive treatment. VAMP2 is therefore thought to be involved in the mechanism of action of antidepressants and may alter their efficacy. The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine. Methods: A total of 106 patients with major depressive disorder were given fluvoxamine (50-200 mg/day) for 8 weeks and assessed for severity of depression using the Semi-Structured Interview Guide of the Hamilton Depressive Scale (SIGH-D; 17 items) at 0 and 8 weeks. We defined a clinical response as more than a 50{\%} reduction in baseline SIGH-D within 8 weeks, and defined clinical remission as a SIGH-D score of less than 7 at 8 weeks. Genotyping was performed by PCR-RFLP. Results: Analysis of haplotype tagging single nucleotide polymorphisms as well as haplotype analysis did not reveal any significant associations. Conclusion: Our results suggest that the VAMP2 gene is unlikely to play a major role in the efficacy of fluvoxamine.",
author = "Shinichi Saito and Nagahide Takahashi and Ryoko Ishihara and Masashi Ikeda and Tatsuyo Suzuki and Tsuyoshi Kitajima and Yoshio Yamanouchi and Nakao Iwata and Mitsuhiko Yamada and Keizo Yoshida and Toshiya Inada and Norio Ozaki",
year = "2007",
month = "4",
day = "1",
doi = "10.1159/000100777",
language = "English",
volume = "54",
pages = "226--230",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "4",

}

Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. / Saito, Shinichi; Takahashi, Nagahide; Ishihara, Ryoko; Ikeda, Masashi; Suzuki, Tatsuyo; Kitajima, Tsuyoshi; Yamanouchi, Yoshio; Iwata, Nakao; Yamada, Mitsuhiko; Yoshida, Keizo; Inada, Toshiya; Ozaki, Norio.

In: Neuropsychobiology, Vol. 54, No. 4, 01.04.2007, p. 226-230.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients

AU - Saito, Shinichi

AU - Takahashi, Nagahide

AU - Ishihara, Ryoko

AU - Ikeda, Masashi

AU - Suzuki, Tatsuyo

AU - Kitajima, Tsuyoshi

AU - Yamanouchi, Yoshio

AU - Iwata, Nakao

AU - Yamada, Mitsuhiko

AU - Yoshida, Keizo

AU - Inada, Toshiya

AU - Ozaki, Norio

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Background: Vesicle-associated membrane protein 2 (VAMP2) is a key component of the synaptic vesicle docking/fusion machinery and its mRNA reportedly increases in the frontal cortex of rats following chronic antidepressant and electroconvulsive treatment. VAMP2 is therefore thought to be involved in the mechanism of action of antidepressants and may alter their efficacy. The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine. Methods: A total of 106 patients with major depressive disorder were given fluvoxamine (50-200 mg/day) for 8 weeks and assessed for severity of depression using the Semi-Structured Interview Guide of the Hamilton Depressive Scale (SIGH-D; 17 items) at 0 and 8 weeks. We defined a clinical response as more than a 50% reduction in baseline SIGH-D within 8 weeks, and defined clinical remission as a SIGH-D score of less than 7 at 8 weeks. Genotyping was performed by PCR-RFLP. Results: Analysis of haplotype tagging single nucleotide polymorphisms as well as haplotype analysis did not reveal any significant associations. Conclusion: Our results suggest that the VAMP2 gene is unlikely to play a major role in the efficacy of fluvoxamine.

AB - Background: Vesicle-associated membrane protein 2 (VAMP2) is a key component of the synaptic vesicle docking/fusion machinery and its mRNA reportedly increases in the frontal cortex of rats following chronic antidepressant and electroconvulsive treatment. VAMP2 is therefore thought to be involved in the mechanism of action of antidepressants and may alter their efficacy. The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine. Methods: A total of 106 patients with major depressive disorder were given fluvoxamine (50-200 mg/day) for 8 weeks and assessed for severity of depression using the Semi-Structured Interview Guide of the Hamilton Depressive Scale (SIGH-D; 17 items) at 0 and 8 weeks. We defined a clinical response as more than a 50% reduction in baseline SIGH-D within 8 weeks, and defined clinical remission as a SIGH-D score of less than 7 at 8 weeks. Genotyping was performed by PCR-RFLP. Results: Analysis of haplotype tagging single nucleotide polymorphisms as well as haplotype analysis did not reveal any significant associations. Conclusion: Our results suggest that the VAMP2 gene is unlikely to play a major role in the efficacy of fluvoxamine.

UR - http://www.scopus.com/inward/record.url?scp=34147117692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147117692&partnerID=8YFLogxK

U2 - 10.1159/000100777

DO - 10.1159/000100777

M3 - Article

C2 - 17356306

AN - SCOPUS:34147117692

VL - 54

SP - 226

EP - 230

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 4

ER -